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Abstract  
Context: The aim of this study is to reviewing various approaches for dealing with agitated patients in 
emergency department (ED) including of chemical and physical restraint methods.  
Evidence acquisition: This review was conducted by searching “Violence,” “Aggression,” and “workplace 
violence” keywords in these databases: PubMed, Scopus, EmBase, ScienceDirect, Cochrane Database, and 
Google Scholar. In addition to using keywords for finding the papers, the related article capability was used to 
find more papers. From the found papers, published papers from 2005 to 2018 were chosen to enter the paper 
pool for further review. 
Results: Ultimately, 200 papers were used in this paper to conduct a comprehensive review regarding violence 
management in ED. The results were categorized as prevention, verbal methods, pharmacological 
interventions and physical restraint. 
Conclusion: In this study various methods of chemical and physical restraint methods were reviewed so an 
emergency medicine physician be aware of various available choices in different clinical situations for agitated 
patients. 
Key words: Aggression, Emergency Service, Hospital, Restraint, Physical, Violence 
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CONTEXT  
Workplace Violence (WPV) of medical personnel 
has diverse forms, accounting for one of the 
potential risk factors in society (1-7). Among 
different jobs, medical personnel are the most 
vulnerable groups to WPV; some studies have 
shown that the probability of WPV for medical 
personnel is higher than that for police officers and 
prison guards (8). Today, accurate statistics of WPV 
are not available for some reasons such as 
unavailability of a unique definition and effective 
deterrent rules (9-11). However, based on 
available data, 35 to 80% of medical personnel, 
especially emergency department (ED) personnel, 
experienced physical violence at least once, and 
100% of them experienced verbal violence in their 
career (12-14). WPV is highly prevalent as almost 
25% of respondents in one study in the United 
States that was published in 2009, reported 
experiencing physical violence more than 20 times 
in the past 3 years (15). WPV is associated with 
severe financial and psychological costs such as 
career burnout, depression, fear, post raumatic 
stress disorder (PTSD), decreased job satisfaction, 
reduced performance, or even career quitting (9, 
16-18). This phenomenon, in addition to the 
medical personnel, can harmfully affect the 
offender and the other patients, as there are some 
reported cases of death following excited delirium 
(19). Among the different departments of hospitals, 
the emergency department is one of the most 
vulnerable departments toward violence of the 
patients; one of its reasons is lack of well-trained 
and armed security guards that are apparent to 
patients (12, 20-22). Stressful and special 
conditions of the emergency department and 
critical state of its patients are other reasons for the 
stimulus of physical and verbal violence toward its 
personnel (20). The constant rising violence 
phenomenon in emergency departments has been 
highly discussed in numerous studies (23-25), and 
some government agencies have tried to establish 
deterrent rules against WPV via intensifying the 
punishment of offenders (26-28). However, based 
on evidence and experience of medical personnel, 
these rules alone, are not competent enough and in 
many cases, direct act from medical personnel is 
needed. The importance and high prevalence of 
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this phenomenon and the need of knowing 
effective approaches for medical personnel to 
control and act directly in WPV situations were the 
purposes of this review article. 
EVIDENCE ACQUISITION 
This review was conducted by searching 
“Violence,” “Aggression,” and “workplace violence” 
keywords in these databases: PubMed, Scopus, 
EmBase, ScienceDirect, Cochrane Database, and 
Google Scholar. In addition to using keywords for 
finding the papers, the related article capability 
was used to find more papers. From the found 
papers, published papers from 2005 to 2018 were 
chosen to enter the paper pool for further review. 
As this article was conducted as a review, no 
independent data from direct clinical interventions 
or field collection were entered the study; 
therefore, no written consent was needed. 
Ultimately, 200 papers were used in this paper to 
conduct a comprehensive review of the 
management of violence in ED.  
RESULTS 
Ultimately, 200 papers were used in this paper to 
conduct a comprehensive review regarding 
violence management in ED. The results were 
categorized as prevention, verbal methods, 
pharmacological interventions and physical 
restraint. 
Prevention 
One of the highly recommended methods in many 
articles is to train medical personnel to determine 
and take necessary measures with the patients in 
the edge of losing control; as these courses are 
mandatory in some healthcare centers (29). 
However, some studies have questioned the 
effectiveness of these courses (30). Among the 
medical personnel, triage nurses are the first line 
exposed to violence and aggression of clients (25, 
31, 32). Therefore, the ability to determine the 
alarming signs of the beginning of violence is highly 
essential in preventing and taking proper actions. 
Among the different methods of screening and 
identification of warning signs of violence, STAMP 
(33), STAMPEDAR (34) are the fastest and most 
practical methods useable in triage. In addition, 
other used methods include Brief Agitation Rating 
Scale (35), Clinical Global Impression Scale for 
Aggression (36), Historical-Clinical-Risk 
Management-20 Violence Risk Assessment Scheme 
(37), and Positive and Negative Syndrome Scale-
Excited Component (38-41). 
Violence management in emergency 
Actions used to manage the patient with violence 
episode in an emergency environment consist of 
verbal, physical, mechanical methods and various 
pharmacological methods that can be combined 
based on situations (42, 43). As there are 
possibilities of physical and psychological harm, 
retraumatization, loss of dignity, and even death, 
especially in physical and mechanical restraint (44, 
45), it is necessary to identify the advantages and 
disadvantages of every method to choose the best 
option. As evidenced by some studies, contrary to 
old methods and beliefs, it is recommended that 
use of mechanical and physical restraint should be 
reduced to significantly decrease the complications 
and prevent the patient isolation, which can 
predispose future violent actions (44, 45). Most 
medical personnel consider control of violence and 
agitation of the patient an easy task, particularly in 
recent years, haloperidol use has increased In 
emergency departments (46-49). However, some 
studies have shown that this drug and controlling 
method has not shown desirable results all the 
time. In the following, different methods of 
managing violence in patients in the emergency 
environment will be reviewed. 
Verbal methods 
The first task when confronting a patient with 
violent and agitated behavior is the evaluation and 
improvement of the environmental setting to 
increase the security of people on stage (50). In line 
with the mentioned task, some rules should be 
generally considered: 
 Assuring patient’s physical safety 
 Reducing environmental triggers and isolating 
the patient 
 Reducing the patients waiting time 
 Removing potentially dangerous objects 
 Observing and evaluating the used approach by 
healthcare staff toward the patient 
 Making efforts toward establishing a safe, 
private, and caregiving communication with the 
patient, and staying calm 
 Maintaining safe distance with the patient 
 Identifying possible causes of patients violence 
 Respecting and maintaining the privacy of the 
patient 
 Avoiding direct and harsh encounter with the 
patient 
 Avoiding prolonged and intense direct eye 
contact with the patient 
 Avoiding using any threatening body language 
The very first therapeutic method in approach 
toward the agitated and aggressive patient is 
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verbal de-escalation (Defusing or talking down). 
This method helps the patient to understand the 
empathy and professional concern of the medical 
personnel and assure the patient that purpose of 
the medical team is his/her well-being and safety, 
and no danger threats him/her (50). In some 
situations, and if available, help and consults from 
social services consultants can also be used (51). 
Pharmacological interventions 
 First-generation antipsychotics (Typical) 
First-generation antipsychotics (FGAs) are more 
commonly used drugs to control and treat 
aggression and agitation in patients (52), and their 
effects are due to inhibition of dopaminergic 
transmission in the brain (46). Despite the 
widespread use of these drugs, their effectiveness 
and side effects are among the discussed issues in 
the studies (52). Usage of these drugs has potential 
risks for development of extrapyramidal and 
tardive dyskinesia side effects (53). 
Based on high- or low-potency, these drugs are 
divided as follows: 
 The first division, the high-potency FGAs consist 
of fluphenazine, haloperidol, loxapine, 
perphenazine, pimozide, thiothixene, and 
trifluoperazine 
 The second division, the low-potency FGAs 
consist of chlorpromazine and thioridazine 
Among the first division drugs, fluphenazine, 
haloperidol, loxapine, pimozide, and thiothixene 
have the highest risk for development of 
Extrapyramidal Syndrome (EPS) (53). Based on 
one study by Gao et al., 21 to 31% of patients under 
treatment with haloperidol for 3 to 8 weeks 
developed drug-induced EPS (54). The second 
division drugs of FGAs have a lower risk of EPS 
development and are comparable with the second-
generation antipsychotics drugs such as 
risperidone (55). 
A) Haloperidol 
Haloperidol is a highly potent neuroleptic that can 
induce a proper sedative effect if administrated 
intramuscular (56). Despite the side effects of this 
drug that can occur even after one-time injection, it 
is still used worldwide in emergency set-up (47, 
51) and the main reasons for that are lower 
complications such as excessive sedation and 
hypotension compared to the same generation 
drugs (48, 57, 58). However, haloperidol alone, can 
induce dangerous EPS complications such as acute 
dystonia (59). In addition to EPS, studies have 
shown that high doses of intravenous haloperidol 
can cause prolonged QT and TdP in 
electrocardiogram (60-65). These complications 
have become more prominent considering the fact 
that haloperidol is the most used drug for 
controlling acute agitation in the world , and it is 
the treatment of choice in some healthcare centers 
(46, 51). 
B) Chlorpromazine  
Discovery of chlorpromazine in 1952 was named 
the “psychopharmacological revolution” in the 
treatment of psychological diseases (66, 67). 
Nevertheless, future studies showed that use of this 
drug for rapid tranquilization was not a suitable 
choice in clinical settings due to local 
hypersensitivity and discomfort following 
intramuscular injection. Furthermore, there is a 
well-documented potential risk for cardiovascular 
disease when using needed doses of this drug for 
rapid tranquilization of the patient (68). However, 
in a Cochrane review conducted by Ahmed et al., no 
statistically significant difference was found 
between EPS complications owing to using 
haloperidol and chlorpromazine (69). 
 Second-generation antipsychotics (Atypical) 
The newest turning point in the treatment of 
psychosis and acute agitation in patients has been 
the production of second-generation 
antipsychotics (Atypical) that have less EPS 
complications (70, 71), hyper prolactinoma (72), 
and movement disorders (58, 71) compared to 
their previous generations. The most important 
drugs of this generation are Risperidone, 
Olanzapine, Ziprasidone, Aripiprazole, and 
Quetiapine (73, 74). In some drugs of this 
generation (e.g. risperidone and olanzapine), there 
is a direct relation between the administered dose 
and incidence of EPS, whereas in some other drugs 
(e.g. clozapine and quetiapine), this relation is not 
apparent (71). It is important to point out that 
some trials have questioned the advantages of 
these antipsychotics in speed on onset (75) and 
degree of response (76, 77) compared to the 
previous generation and even haloperidol alone 
(78, 79), and even some studies have considered 
this two generation to have a one category (46, 80). 
Furthermore, notwithstanding the benefits of this 
generation of drugs and their superiority in 
reducing morbidity and mortality, their prolonged 
use can induce complications such as 
overweighting, disruption of glucose metabolism, 
dyslipidemia, and cardiovascular disease (81). 
Based on available guidelines, to control the 
patient's symptoms, monotherapy is preferred 
over polytherapy, and according to a general rule, 
an administrated dose of the drug should be equal 
to 300 to 1000 chlorpromazine to reduce the 
incidence of a dangerous side effect (82, 83). One of 
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the main problems of using atypical antipsychotic 
drugs in an emergency is a limited number of the 
performed randomized clinical trial concerning 
these drugs in emergency setup (80, 84-91). Many 
of the studies into using these drugs have been 
conducted on recently admitted agitated patients 
(79, 92, 93). This can be one of the main obstacles 
facing emergency medicine physicians when 
choosing and using these drugs. Nevertheless, most 
of the conducted studies in different hospital 
settings confirm high effectiveness of these drugs 
compared to haloperidol (Either same 
effectiveness or higher) in the treatment of the 
agitated patient (79, 87, 91, 94, 95). 
A) Risperidone  
It is a second-generation antipsychotic drug 
administered in variable ways (96); even in its oral 
intake form (Risperidone OS), it is efficient as much 
as other forms (97). Furthermore, there is no 
statistically significant difference between the oral 
form of risperidone and injected haloperidol 
regarding compliance, the speed of onset, and 
effectiveness (98). Villari et al. in their study 
observed that risperidone, olanzapine, and 
quetiapine were effective as much as haloperidol, 
and interestingly they showed its better 
compliance compared to haloperidol (99). In 
addition to its advantageous position to atypical 
antipsychotics, it has shown equal or better action 
compared to some typical antipsychotics such as 
zuclopenthixol (100). 
B) Olanzapine  
Olanzapine is one of the second-generation 
antipsychotics and is a dopamine/serotonin 
antagonist that Its effect on controlling and 
relaxing patients in the injectable and oral 
administration is higher than intramuscular 
haloperidol in the first 90 minutes and after that, 
the effects are equal (96). According to the study of 
Pascual et al., oral administration of 20 milligrams 
of olanzapine was effective in rapid and safe 
improvement of acutely agitated patients (101). 
Although oral administration of olanzapine 
(Olanzapine ODT) is more effective than its 
injectable form, studies have not shown any 
statistically significant difference (96). Since 
intramuscular administration of olanzapine is 
effective and safe in improving and treating 
agitated patients (102, 103), choosing between 
different forms of administration is related to 
circumstances and physician’s opinion. In one 
study by Castle et al., intramuscular administration 
of olanzapine compared to other antipsychotics 
was more effective in improving patients’ 
symptoms two hours after administrations, and the 
results were statistically significant (104); there 
are more studies confirmative of this result (84, 
90). In this regard, studies have indicated better or 
equal effects of olanzapine compared to 
haloperidol (99, 105, 106). Other advantages of 
olanzapine use in managing agitated patients are 
that the need for other antipsychotic, 
anticholinergic, and anxiolytic/hypnotic drugs 
administration is reduced compared to other drugs 
(104, 107). In one study by Kinon et al., no 
statistically significant difference was found 
between the effects of using olanzapine and 
aripiprazole (both with co-administration of 
lorazepam). The most observed side effect in 
olanzapine use was insomnia (5.2%) and in 
aripiprazole was insomnia (8.3%) and headache 
(5.3%) (108). It is important to know that 
concurrent administration of intramuscular 
olanzapine with benzodiazepines increases the 
probability of occurring side effects (109-111); 
olanzapine can affect the Alpha-1 receptors and 
induce hypotension (112). 
C) Quetiapine  
In contrast to other atypical antipsychotics and like 
olanzapine, it has a high affinity toward 
antihistaminic receptors; therefore, it poses a 
higher sedative effect on the patient compared to 
other drugs of its generation (48). Drowsiness and 
orthostasis are among the most reported side 
effects of this drug. These side effects can be a 
limiting factor for their use in patients with 
dehydration and electrolytes imbalance (113, 114). 
D) Ziprasidone  
Ziprasidone was the first drug of atypical 
antipsychotic drugs in injectable form (86). 
Compared to other atypical antipsychotic drugs, its 
affinity toward serotonin receptors compared to 
D2 receptors is 10-folds (115). Based on conducted 
clinical trials, this drug can improve the symptoms 
of an agitated patient in 15-30 minutes (116). 
Though this drug like other drugs in its generation 
has lower side effects (e.g.  EPS, dystonia, and 
oversedation), but the danger of QTc prolongation 
and cardiac arrhythmia still exist (117). Despite 
this, Jangro et al. study showed that monotherapy 
with intramuscular ziprasidone could induce an 
effective and relevant sedative effect compared to 
the combined use of haloperidol and lorazepam 
(86). 
E) Aripiprazole 
Among the variable atypical antipsychotic drugs, 
there is Aripiprazole that different studies have 
showed its high effectiveness (up to 90% of 
patients) in intramuscular administration (92, 93, 
118). No statistically significant relationship has 
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been found between clinical effectiveness and its 
blood serum levels; this is similar to most of the 
atypical antipsychotics drugs (except olanzapine 
(118-120). This is one of the challenges ahead of 
clinical practice in using Aripiprazole that can 
affect acquiring therapeutic levels and controlling 
its side effects. However, some of its side effects 
such as sedation can be compared to drugs such as 
lorazepam; as in one study by Zimbroff et al., levels 
of effectiveness of Aripiprazole were the same as 
intramuscular lorazepam, but it showed lower 
sedative effects (92). 
 Benzodiazepines 
Benzodiazepines, with their anxiolytic and sedative 
effects, can cause rapid agitation of the patient. 
However, their side effects such as respiratory 
depression, excessive sedation, ataxia, and 
paradoxical disinhibition limit their usage (46, 
121-128). 
A) Lorazepam 
Other drugs that can be used to control patients 
with agitation are lorazepam, which has positive 
outcomes particularly in combination with 
haloperidol (91); therefore, the most commonly 
used antipsychotic combination in the United 
States is haloperidol+lorazepam (129). However, a 
2005 Cochrane review study found that there was 
insufficient evidence to suggest a superior benefit 
in a combination of haloperidol+lorazepam than 
other antipsychotics such as 
haloperidol+promethazin (130). In addition, its IM 
form is not readily available in many regions (56). 
B) Diazepam and Midazolam 
Diazepam along with haloperidol, lorazepam, 
midazolam, and chlorpromazine have been 
controversial in tolerability profiles in studies 
(131). Among these drugs, diazepam and 
midazolam have a potential risk for respiratory 
depression, especially in high-risk patients and 
those with metabolic disorders of benzodiazepines 
(such as hepatic impairment and alcohol users) 
(131-133). Diazepam, as with lorazepam, is also 
contraindicated in patients suspected of being 
poisoned with Propylene glycol (131). Despite 
these complications, some studies have indicated 
better effects of midazolam on psychomotor 
agitation than haloperidol (73). 
 Other drugs 
A) Promethazine 
Studies have shown that this anti-histamine, 
especially in combination with haloperidol (59), 
can be useful in acute improvement of the patient's 
agitation in emergencies. The reason for this drug 
combination is to accelerate the final results 
following sedative and antimuscarinic effects of 
promethazine (56, 80, 117, 129). However, the 
combination of this drug with olanzapine is not 
recommended due to increased likelihood of 
symptomatic hypotension, particularly in alcohol 
users (112, 134). 
Physical restraint 
Physical restraint refers to a set of actions taken on 
the body or near the patient's body to limit the 
degree of freedom of movement (135, 136). 
Restraining the patients is performed in two ways: 
Physical restraining whereas some areas of the 
patient's body is held by other people and 
mechanical restraining whereas the movements of 
the patient are limited by using approved devices 
and appliances such as straps (leather and cloth) 
and belts (18, 137-140). Most of the times, the term 
“physical restraint” is used to refer to the two 
above-mentioned ways. Physical restraint is 
performed in various ways: limiting the 
movements of limbs and body on specific beds with 
straps [4 points (ankles and wrists) and 5 points 
(ankles, wrist, and chest)]; fasten the patient on 
chair and limiting the movements of limbs 
(Ambulatory restraint); limiting the whole-body 
movement by camisole or straightjacket. When 
restraining patients, there should be some 
considerations: either restraint the 4 limbs or none, 
since freedom of one limb can cause many 
problems and complications; to prevent kicking 
from the patient, right leg can be tied up to the left 
corner of the bed, and the left leg can be tied up to 
the right corner of the bed; using a soft padding 
beneath the skin of restrained ankles and wrists; 
unlocking the fastened parts of the patient’s body 
in periodical manner to prevent the possible 
complications; moving the body of the patient 
every 2 hours; examination distal of the limbs for 
sensory and neurological signs; immobilizing the 
chest or waist to prevent falling down from the bed; 
checking patients respiratory rate every hour; for 
patients that are in the wheelchair, chest should be 
immobilized not the waist (141-143).  
There are some rules provided by “American 
College of Emergency Physicians (ACEP)” for 
physical restraint usage (144):  
 It should be used only after verbal de-escalation 
 Privacy and dignity of the patient should be 
maintained during the physical restraint  
 Limitation should be as low as possible  
 Medical personnel should be properly trained 
for using physical restraint and monitoring the 
patient under physical restraint  
 The existence of appropriate protocols to 
ensure patient safety, including the necessary 
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care and treatment during the period of physical 
restraint and periodic evaluations to determine 
whether to maintain physical restraint  
 The patient under physical restraint should be 
explicitly and continuously observed by his or 
her physician  
 The use of physical restraint should be 
consistent with standards and rules.  
Owing to the possibility of complications and the 
use of physical restraint, which may be subject to 
pressure and threats and punishment, it is difficult 
to make decisions about physical restraint (142).  
 
DISCUSSION 
Based on conducted studies, a significant portion of 
violence in an emergency environment is caused by 
patients (88.2%) aged between 20 and 30 years, 
and with male sex (64.7%). Alcohol use (52.3%), 
methamphetamine and other drugs abuse (5%), 
long waiting hours (11.9%) (11, 145-147), suicidal 
thoughts (13.8%) (145), high severity of previous 
violence of patient (148), inadequate number of 
personnel (149), weak safety proceedings (150), 
an out-of-sight security team (151, 152), crowded 
and busy emergency unit (153), time of the patient 
arrival (evening and night shifts) (23), and weak 
ability of medical personnel in communicating with 
the patient and patient companion (154) are 
among the influencing factors (155). 
Pharmacological interventions in the management 
of violent patients in emergency departments 
consist of using first-generation antipsychotics 
(especially haloperidol), benzodiazepines, and 
second generations antipsychotics (atypical). The 
most important fact that should be considered 
when choosing drugs is that the primary purpose 
of managing the violent patient in the emergency 
department is calming down and reducing 
agitation not over sedating the patient (73, 91, 156-
159). 
Physical restraint should provide acceptable 
protection against injury for the patient and others. 
Aggressive behavior can occur suddenly, and it 
should be considered that in the every moment, it 
occurs, the first reaction for controlling it, should 
always be verbal de-escalation (135, 160). Physical 
restraint is used when verbal de-escalation and 
pharmacological intervention are not effective, and 
the patient has dangerous and harmful behaviors 
for himself/herself and others (135, 161, 162). The 
goals of physical restraint are preventing harm and 
injury to physical and psychological integrity, and 
safety of the patient and other patients and medical 
personnel; preventing severe damage to the 
healthcare center environment (135, 142, 163). 
Furthermore, physical restraint can provide a way 
for performing necessary therapeutic actions and 
grant the time for administrated drugs to reach 
their therapeutic levels (135, 162, 164, 165). From 
the beginning of the physical restraint, the reason 
for it should be declared for the patient so that it 
should be explained to the patient that the purpose 
of this action is not punishment and it is for the 
safety of the patient and others (161, 166). Physical 
restraint is always accompanied by numerous 
dangers and complications. Therefore, specific and 
detailed rules and instruction for its use should be 
available in every healthcare center. 
Various factors affect the decision-making of 
medical personnel to apply physical restraint, 
including lack of alternative ways, underlying 
needs, escalation effects of restraint itself, and so 
on (167). Several hazards to the patient under 
physical restraint may occur, including the 
following: dehydration, choking, blood circulatory 
problems in under pressure areas and limbs, 
bedsore, losing power and movement by the 
patient, incontinence, thromboembolic incidents, 
Deep Vein Thrombosis, bone fracture, lactic 
acidosis, aspiration, stress cardiomyopathy, 
respiratory depression and asphyxia, and even 
death (57, 168-176). Preventing these 
complications is achieved via periodic and constant 
evaluations (166). 
In one study by Cowman et al. conducted in 17 
European countries, among mental health 
personnel (mental inpatient services, forensic, 
emergency, and so on), the results showed that the 
most common method of intervention against 
violence was to use physical restraint (177). One 
study showed that there was limited empirical 
evidence for using physical restraint to control the 
violence of admitted mentally ill patients (178). 
The use of physical restraint in mental patients, if 
not controlled, can tend to increase (179). One 
study in China showed a positive correlation 
between the use of physical restraint, 
unemployment, low incomes, and the amount of 
patients’ aggression in the last month (180). In 
some countries such as Britain and the 
Netherlands, mechanical and physical restraint is 
against the law (57, 181). In Brazil, the most 
common way of controlling violence and invasion 
is to use physical restraint (57).  
In recent years, many efforts have been made to 
reduce the use of physical restraint. In one study, a 
six-core strategy based on “Trauma Informed care” 
was used between young patients admitted to the 
hospital, the results showed that this strategy 
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reduced the use of physical restraint in young 
patients admitted to hospital. The main causes of 
using physical restraint were maladaptive 
behavior and mood disorders (182). Another study 
conducted on hospitalized patients in New York 
City could significantly reduce the amount of 
physical restraint during a 5-year period follow-up 
by employing several interventions, including 
reducing the timing of new orders for physical 
restraint, teaching staff to diagnose patients at risk 
for immediate intervention, and a questionnaire 
filled by patients that determined their own 
choices in When anxiety was detected (183). In one 
study by Martin et al., a "Collaborative problem 
solving" treatment program for children and adult 
patients reduced the use of physical restraint in 
children (184). 
Owing to cultural and regional differences, it is 
difficult to create a universal protocol for using 
physical restraint. Physical restraint can influence 
the rate of acceptance of post-discharge treatment 
interventions by the patient after being discharged 
from the emergency department. In one study, the 
effect of physical restraint on the rate of referral for 
outpatient psychiatric visits after discharge was 
examined. The results showed that patients with 
physical restraint were less likely to conduct these 
post-discharge visits (185). In one study, the 
abundance and type of physical restraint used by 
ICU, emergency department, and neurosurgery 
nurses, their views on physical restraint, as well as 
the complications of this work in several hospitals 
in Turkey were investigated. Nurses performed 
physical restraint on ankle, hand or body at 
different levels. Those working in the surgical and 
emergency ICU sections having in-service training 
used more physical restraint. There were also 9 
deaths. The reduction in the rate of services to 
patients was directly related to the complications 
of physical restraint (186). In one retrospective 
study conducted in a hospital over a 1-year period 
in patients with acute behavioral disorders 
referred to the emergency department that needed 
intervention, the results showed that from 122 
cases with this condition, physical restraint alone 
was performed in 14 cases, and it was performed 
along with pharmacological therapy in 66 cases 
(187). In another study conducted by Dumais et al., 
results from a mental hospital in Canada showed 
that over 2 years, out of 2721 admitted patients, 
physical restraint was used in 476 cases (188). In 
another study, the use of physical restraint in 
patients over the age of 60 was determined by 
nurses to be patient safety and nurses' workload 
(189, 190). In another study in the emergency 
department of four hospitals in Australia, results 
showed that physical restraint was used in 0.04% 
of the total number of referrals. The physical 
restraint was mainly carried out using a soft 
bracelet and soft sole. The average physical 
restraint time was 2 hours and 5 minutes (191). 
There is a considerable difference between 
duration of physical inhibition in different areas. In 
one study, the average physical restraint time in 10 
European countries varied from 4.5 hours to 1182 
hours (137, 192). In one study, the relationship 
between the degree and type of physical restraint 
with age and sex and the history of immigration in 
a hospital in Norway was investigated. The results 
indicated that from 960 hospitalized patients, in 
14% of them, physical restraint was used. Physical 
restraint was higher among immigrants and 
especially young people. Physical restraint alone 
was higher in local people, and along with drug 
interventions, it was higher in immigrants. Physical 
restraint was reduced at the age of 60 or more 
(193). 
In one study investigating the first physical 
restraint experience in psychiatric wards over 2 
years, the results indicated that physical restraint 
along with pharmacological intervention took 
longer than physical restraint alone (194). Another 
study found that patients who were periodically 
subjected to physical restraint were hospitalized 
more often and longer (195). In one study, the 
patients' opinion about physical restraint and 
possible improvement and alternative were 
investigated. The results demonstrated that failure 
to address and provide the patients’ basic needs 
and lack of communication during the time of 
physical restraint were the most important factors 
among the mentioned problems (196). In another 
study, the study of patients' perceptions and 
impressions subjected to physical restraint 
revealed that patients were inadequately 
connected with medical staff and feel distorted and 
trampled on their human rights (197). Another 
study conducted by McCurdy et al. demonstrated 
that installation of a door between the patients’ 
accessible area and the waiting area of the ward, 
significantly reduced the amount of physical 
restraint (198). A study performed in 3 psychiatric 
emergencies in Rio, Brazil on aggressive patients 
showed that of 301 patients, 73 of them were 
physically restrained in the first 2 hours after 
admission (199). Physical restraint can undermine 
the trust and relationship between the patient and 
the medical team members. A series of factors can 
reduce this damage. In this regard, one study by 
Khatib et al. showed that duration of the restraint, 
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contact with medical personnel during the period 
of physical restraint, supportive interventions of 
medical personnel and their response to the 
patient's needs were critical and significant factors 
in determining how the patient experienced 
physical restraint and its consequence (200). 
CONCLUSIONS 
In this study various methods of chemical and 
physical restraint methods were reviewed so an 
emergency medicine physician be aware of various 
available choices in different clinical situations for 
agitated patients. 
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